Calidi Biotherapeutics closes $1.2 million registered direct stock offering
The San Diego biotech sold about 1 million shares at $1.17 apiece, with no underwriter involved, closing September 21, 2026.
SEC filing
Latest
4 stories
Tuesday, September 22
Thursday, September 17
Calidi Biotherapeutics prices $1.2 million stock offering at $1.17 per share
The San Diego biotech will sell 1,025,640 shares directly to investors, with delivery expected September 21, 2026, as it flags going-concern doubt.
SEC filing
Thursday, August 13
Calidi gets FDA pre-IND feedback on CLD-401, still targets Q1 2027 first dose
The company said the FDA agreed with its development strategy for the RedTail program's lead candidate, keeping the first-in-human study on track for early 2027.
SEC filing
Thursday, July 16
Calidi Biotherapeutics signs new San Diego lease, ends current one early
The company will move to a new office and lab space in October 2026 and expects to save about $1.1 million a year in rent and facility costs.
SEC filing